A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity

Health Technology Assessment

Volumn 5, Issue 18, 2001, Pages

  O'Meara, S ^a   Riemsma, R ^a   Shirran, L ^a   Mather, L ^a   Ter Riet, G ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; PLACEBO; TETRAHYDROLIPSTATIN;

BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; OBESITY; PATIENT COUNSELING; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE;

EID: 0034981161     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta5180     Document Type: Review

References (65)

1. Obesity
2. Obesity in Britain: Gluttony or sloth?
3. Familial trends of obesity through three generations: The Belgian-Luxembourg child study
4. Internal medicine, obstetric and gynecological problems related to overweight
5. Childhood predictors of adult obesity: A systematic review
6. The influence of smoking cessation on the prevalence of overweight in the United States
7. Pathophysiology of obstructive sleep apnoea
8. Sleep-disordered breathing and obesity
9. The prevalence of obstructive sleep apnoea in an obese female population
10. The sleep apnoea syndrome in obesity: Risk of sudden death
11. Waist circumference action levels in the identification of cardiovascular risk factors: Prevalence study in a random sample
12. The influence of body fat distribution on the incidence of diabetes mellitus
13. Greater influence of central distribution of adipose tissue on incidence of non-insulin diabetes in women than in men
14. Beneficial effects of modest weight loss
15. Change in body weight and longevity
16. Larger fluctuations in body weight during young adulthood and twenty-five-year risk of coronary death in men
17. Variability of body weight and health outcomes in the Framingham population
18. Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial
19. Does weight cycling present a health risk?
20. Periodic health examination, 1999 update. 1. Detection, prevention and treatment of obesity
21. Chapter 70: Obesity
22. Cochrane reviewer's handbook 4.1
23. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
24. Lipase inhibition: A novel concept in the treatment of obesity
25. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study
26. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
27. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial
28. Orlistat in the long-term treatment of obesity in primary care settings
29. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
30. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study
31. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia
32. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
33. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
34. Assessing health-related quality of life and health state preference in persons with obesity: A validation study
35. Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet
36. Intent-to-treat analysis for longitudinal studies with drop-outs
37. Orlistat and weight loss
38. Orlistat and weight loss - Reply
39. Improving the quality of reporting of randomized controlled trials - The CONSORT statement
40. Establishing a standard definition for child overweight and obesity worldwide: International survey
41. Adolescent obesity, a need for greater awareness and improved treatment
42. Helping obese youngsters lose weight: What works...What doesn't?
43. Drug therapy for obesity in the elderly
44. An overview of age-specific pharmacokinetics and pharmacodynamics
45. Gender-specific aspects of obesity